Table 3.
Preoperative markers, bcl-2 and cathepsin–L serum concentrations depending on the method of treatment at serous tumors only
| Primary optimal cytoreduction | Neoadjuvant chemotherapy | p | |
|---|---|---|---|
| CA125 [IU/ml] |
|
|
|
| Mean |
455.1 |
2661.46 |
|
| Median |
167.25 |
600.0 |
p = 0.0019 |
| Range |
(15.81-2377.0) |
(49.22-22982.0) |
|
| HE4 [pmol/l] |
|
|
|
| Mean |
87.62 |
560.7 |
|
| Median |
24.78 |
564.72 |
p = 0.0009 |
| Range |
(2.5-775.79) |
(45.82-1310.69) |
|
| YKL-40 [ng/ml] |
|
|
|
| Mean |
128.73 |
203.37 |
|
| Median |
84.23 |
200.24 |
p = 0.005 |
| Range |
(16.42-417.27) |
(45.02-437.01) |
|
| Cathepsin-L [ng/ml] |
|
|
|
| Mean |
12.95 |
12.81 |
|
| Median |
84.23 |
10.98 |
p = 0.8125 |
| Range |
(8.42-28.87) |
(8.53-46.45) |
|
| bcl-2 [ng/ml] |
|
|
|
| Mean |
12.01 |
23.98 |
|
| Median |
20.98 |
20.07 |
p = 0.6913 |
| Range | (11.27-45.53) | (4.88-81.02) |